HealthInvest Partners AB lowered its stake in shares of Charles River Laboratories International Inc. (NYSE:CRL) by 16.1% during the second quarter, Holdings Channel reports. The institutional investor owned 149,612 shares of the company’s stock after selling 28,695 shares during the period. Charles River Laboratories International accounts for 5.7% of HealthInvest Partners AB’s holdings, making the stock its 11th largest position. HealthInvest Partners AB’s holdings in Charles River Laboratories International were worth $12,334,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in CRL. State Street Corp raised its position in Charles River Laboratories International by 3.0% in the first quarter. State Street Corp now owns 1,289,582 shares of the company’s stock worth $97,928,000 after buying an additional 37,420 shares during the period. Canada Pension Plan Investment Board raised its position in Charles River Laboratories International by 4.1% in the first quarter. Canada Pension Plan Investment Board now owns 5,100 shares of the company’s stock worth $387,000 after buying an additional 200 shares during the period. Acrospire Investment Management LLC bought a new position in Charles River Laboratories International during the first quarter worth $327,000. JPMorgan Chase & Co. raised its position in Charles River Laboratories International by 206.5% in the first quarter. JPMorgan Chase & Co. now owns 156,443 shares of the company’s stock worth $11,880,000 after buying an additional 105,399 shares during the period. Finally, Massmutual Trust Co. FSB ADV raised its position in Charles River Laboratories International by 4.4% in the first quarter. Massmutual Trust Co. FSB ADV now owns 2,769 shares of the company’s stock worth $210,000 after buying an additional 117 shares during the period. 96.19% of the stock is owned by institutional investors and hedge funds.

Shares of Charles River Laboratories International Inc. (NYSE:CRL) traded up 1.50% on Wednesday, hitting $81.72. The company had a trading volume of 331,741 shares. Charles River Laboratories International Inc. has a 12-month low of $59.99 and a 12-month high of $89.18. The firm has a market capitalization of $3.86 billion, a P/E ratio of 27.61 and a beta of 1.21. The firm has a 50 day moving average of $82.71 and a 200-day moving average of $81.92.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, August 3rd. The company reported $1.20 EPS for the quarter, beating analysts’ consensus estimates of $1.10 by $0.10. The business earned $434.10 million during the quarter, compared to the consensus estimate of $425.05 million. Charles River Laboratories International had a return on equity of 25.18% and a net margin of 9.49%. The firm’s revenue was up 27.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.96 earnings per share. On average, equities analysts predict that Charles River Laboratories International Inc. will post $4.45 EPS for the current year.

A number of equities analysts recently weighed in on CRL shares. Zacks Investment Research lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Friday, July 22nd. Credit Suisse Group AG assumed coverage on Charles River Laboratories International in a research report on Monday, June 20th. They set a “neutral” rating and a $84.00 price objective for the company. Citigroup Inc. raised their price objective on Charles River Laboratories International from $85.00 to $90.00 and gave the stock a “neutral” rating in a research report on Thursday, August 4th. Jefferies Group raised their price objective on Charles River Laboratories International from $94.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, August 4th. Finally, Evercore ISI restated a “hold” rating and set a $91.50 price objective (up from $83.50) on shares of Charles River Laboratories International in a research report on Thursday, August 4th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and five have assigned a buy rating to the company’s stock. Charles River Laboratories International has a consensus rating of “Hold” and an average target price of $86.21.

In other Charles River Laboratories International news, Director Richard F. Wallman sold 7,740 shares of the business’s stock in a transaction dated Friday, July 29th. The stock was sold at an average price of $88.00, for a total value of $681,120.00. Following the completion of the transaction, the director now directly owns 24,190 shares of the company’s stock, valued at $2,128,720. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Chairman James C. Foster sold 18,351 shares of the business’s stock in a transaction dated Friday, August 5th. The shares were sold at an average price of $85.63, for a total value of $1,571,396.13. Following the completion of the transaction, the chairman now directly owns 383,283 shares of the company’s stock, valued at $32,820,523.29. The disclosure for this sale can be found here. 2.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a full service, early-stage contract research company. The Company is engaged in the business of providing the research models required in research and development of new drugs, devices and therapies. The Company operates through three segments: Research Models and Services (RMS), which consists of Research Models and Research Model Services; Discovery and Safety Assessment (DSA), which offers discovery and safety assessment services, both regulated and non-regulated, in which it includes both in vivo and in vitro studies, and Manufacturing Support (Manufacturing), which includes Microbial Solutions, Biologics Testing Solutions and Avian Vaccine Services.

5 Day Chart for NYSE:CRL

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International Inc. (NYSE:CRL).

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.